RecruitingNCT03217396

Biomarkers of Synaptic Damage in Multiple Sclerosis

Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage

Sponsor

Neuromed IRCCS

Enrollment

300 participants

Start Date

Nov 22, 2017

Study Type

OBSERVATIONAL

Conditions

Amyotrophic Lateral Sclerosis Multiple Sclerosis Alzheimer Disease Parkinson Disease

Summary

A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for biological markers in the blood and spinal fluid that indicate nerve cell damage in people with multiple sclerosis (MS), a disease where the immune system attacks the brain and spinal cord. **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with MS according to standard medical criteria - Your disability level is mild to moderate - You are able to give informed consent **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have abnormal blood counts - You have a condition that prevents MRI with contrast dye (gadolinium) - You have significant other medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.